Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tertiary prevention

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Tertiary prevention. Displaying page 1 of 1.
    EudraCT Number: 2007-005389-11 Sponsor Protocol Number: VAC035 Start Date*: 2009-05-07
    Sponsor Name:University of Oxford
    Full Title: A Phase I/IIa Study of the Safety, Immunogenicity and Parasite Growth Inhibitory Activity of AMA1-C1/Alhydrogel® + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium falciparum Malaria
    Medical condition: Plasmodium falciparum malaria
    Disease: Version SOC Term Classification Code Term Level
    8.1 10036655 Prevention of malaria LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002203-15 Sponsor Protocol Number: PregMet2 Start Date*: 2012-08-08
    Sponsor Name:NTNU, Norwegian University of Science and Technology
    Full Title: Metformin treatment of pregnant PCOS women and prevention of late miscarriages and preterm birth The PregMet 2 Study
    Medical condition: Poly Cystic Ovarial Syndrome (PCOS) in pregnant women. PCOS should be diagnosed according to the Rotterdam Consensus criterias: - at least 2 out of 3 criterias 1.PCO in at least one ovary 2.Olig...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: NO (Completed) SE (Completed) IS (Completed)
    Trial results: View results
    EudraCT Number: 2015-004824-77 Sponsor Protocol Number: 27UCS2015 Start Date*: 2016-06-23
    Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA
    Full Title: A randomized, phase II, double-blind, placebo-controlled, multicenter, 2x2 factorial design biomarker tertiary prevention trial of low-dose aspirin and metformin in resected stage I-III colorectal ...
    Medical condition: Surgical resected colorectal cancer (stage I-III)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002270-29 Sponsor Protocol Number: IN 0401 INT Start Date*: Information not available in EudraCT
    Sponsor Name:LEO Pharma A/S
    Full Title: Safety profile of innohep versus subcutaneous unfractionated Heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis
    Medical condition: Treatment of acute deep vein thrombosis in elderly patients with impaired renal function
    Disease: Version SOC Term Classification Code Term Level
    6.1 10051055 LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Completed) DK (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001069-28 Sponsor Protocol Number: D5881C00004 Start Date*: 2015-02-10
    Sponsor Name:AstraZeneca AB
    Full Title: A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH)
    Medical condition: Severe persistent Hypertriglyceridemia in High Cardiovascular Risk Patients
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) EE (Completed) LT (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015502-19 Sponsor Protocol Number: EMR200136_022 Start Date*: 2009-12-14
    Sponsor Name:Merck Serono SA – Geneva
    Full Title: A multinational, multicenter, single visit, exploratory pharmacogenetic trial and long-term follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Mu...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) DE (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004016-12 Sponsor Protocol Number: Start Date*: 2009-01-21
    Sponsor Name:Lijf en Leven
    Full Title: Clopidogrel for the prevention of late cardiac events in patients with asymptomatic perioperative acute coronary syndrome.
    Medical condition: Study target patients are those with peripheral arterial disease who underwent a major vascular surgery and develop asymptomatic troponine-elevation. These patients are randomised for treatment wit...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034638 Peripheral vascular disorders NEC HLT
    9.1 10018106 Generalized arterial disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000663-45 Sponsor Protocol Number: PREVENT-iT-2021.07 Start Date*: 2023-02-01
    Sponsor Name:Hamilton Health Sciences Corporation
    Full Title: Prospective Randomized Evaluation of Emerging Novel Treatments for Infection prophylaxis in Total Joint Replacement (PREVENT-iT): A Pilot Study
    Medical condition: Persistent Draining Wound and Periprosthetic Joint Infection prevention in patients undergoing total joint replacement
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022746-24 Sponsor Protocol Number: TS-P04834 Start Date*: 2012-05-07
    Sponsor Name:Tesaro, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy- Induced Nausea and Vomiting (CINV) in Subject...
    Medical condition: Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderately Emetogenic Chemotherapy (MEC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10049091 Chemotherapy antiemetic prophylaxis LLT
    14.1 10042613 - Surgical and medical procedures 10054133 Prophylaxis of nausea and vomiting PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LV (Completed) ES (Completed) BE (Completed) CZ (Completed) PL (Completed) BG (Completed) SK (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000140-25 Sponsor Protocol Number: 2003141 Start Date*: 2004-09-08
    Sponsor Name:Procter & Gamble Pharmaceuticals
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of 2 mg/kg Bolus Plus 24-hour 0.05 mg/kg/hr Infusion Pexelizumab in Patients Undergoing Coronary Artery Bypass Graf...
    Medical condition: Prevention of systemic inflammatory response predominantly triggered by the interaction between the patient’s blood and the pump’s artificial surfaces in patients undergoing coronary artery bypass ...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10006894 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001402-38 Sponsor Protocol Number: CTU/2020/352 Start Date*: 2020-10-20
    Sponsor Name:University College London
    Full Title: An international, Bayesian platform adaptive, randomized, placebo-controlled trial assessing the effectiveness of candidate interventions in preventing COVID-19 disease in healthcare workers.
    Medical condition: Coronavirus disease 2019 (COVID-19), also known as SARS-CoV-2 infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-004895-37 Sponsor Protocol Number: SPD476-313 Start Date*: 2007-12-19
    Sponsor Name:Shire Pharmaceutical Development Limited
    Full Title: A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence...
    Medical condition: Treatment of Diverticulitis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10013538 Diverticulitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FR (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-000484-86 Sponsor Protocol Number: 02022018 Start Date*: 2019-01-16
    Sponsor Name:Rigshospitalet
    Full Title: DAN-WAR-D Danish Warfarin-Dialysis Study Safety and efficacy of warfarin in patients with atrial fibrillation on dialysis - A nationwide parallel-group open randomized clinical trial
    Medical condition: Atrial fibrillation, end-stage renal disease, and stroke
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004857 10016149 Failure kidney LLT
    20.0 100000004849 10016566 Fibrillation atrial LLT
    22.1 100000004852 10057613 Thromboembolic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-004896-20 Sponsor Protocol Number: SPD476-314 Start Date*: 2008-05-20
    Sponsor Name:Shire Pharmaceutical Development Limited
    Full Title: A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence...
    Medical condition: Treatment of Diverticulitis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10013538 Diverticulitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) DE (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2019-001310-42 Sponsor Protocol Number: BL.13 Start Date*: 2019-10-15
    Sponsor Name:Canadian Cancer Trials Group (CCTG)
    Full Title: A randomized phase II trial assessing trimodality therapy with or without adjuvant Durvalumab (MEDI4736) to treat patients with muscle-invasive bladder cáncer
    Medical condition: Muscle-invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066753 Bladder transitional cell carcinoma stage II PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066754 Bladder transitional cell carcinoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-002654-21 Sponsor Protocol Number: RHMCAN1219 Start Date*: 2017-11-23
    Sponsor Name:University Hospital Southampton NHS Foundation Trust
    Full Title: A PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH-DOSE THERAPY.
    Medical condition: Diffuse large B-cell lymphoma (most common type of non-Hodgkins lymphoma)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 05 14:23:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA